At PHSE, we believe that investing in the education and training of young scientists is essential to advancing cancer research and bringing hope to patients and their families. This belief has inspired us to actively support the work of Fondazione AIRC per la ricerca sul cancro ETS, contributing to the funding of a scholarship for a young researcher specializing in pediatric cancer research.

This commitment is more than an investment; it is a promise to support cutting-edge research and provide hope for the future.

We are proud to announce our participation in the 56th Annual Conference of the Society of Nuclear Medicine India (SNMICON 2024), the premier event for nuclear medicine professionals in India.

SNMICON 2024 serves as an important platform to explore the latest advancements in nuclear medicine, exchange innovative ideas and research, and showcase cutting-edge technologies that are shaping the future of the field. It emphasizes collaboration and innovation as key drivers in advancing nuclear medicine and improving patient care.

PHSE is proud to contribute its expertise as a global leader in radiopharma logistics. With advanced solutions for the transportation of medical isotopes used in diagnostics and therapy, PHSE continues to support the needs of healthcare facilities and production plants worldwide.

By providing temperature-controlled logistics, real-time monitoring of shipments, and secure and efficient delivery systems, PHSE remains committed to supporting the nuclear medicine community and fostering advancements that benefit patients globally.

We are proud to announce the expansion of our fleet with new dedicated radiopharma vehicles, further enhancing our licensed network for the transport of medical isotopes used in diagnostics and therapy. These vehicles are engineered to meet the highest standards for the safe and efficient delivery of radiopharmaceuticals by both road and air, offering comprehensive global support to healthcare facilities and production plants.

The newly added vehicles are equipped with state-of-the-art temperature-controlled systems, ADR-compliant technology, and GPS geolocation to ensure precise tracking. Fully compliant with Class 7 regulations across all operational territories, these vehicles reflect PHSE’s unwavering commitment to safety, reliability, and efficiency in the transport of radiopharmaceuticals.

This initiative underscores PHSE’s leadership in radiopharmaceutical logistics, delivering innovative and reliable solutions that prioritize patient care and operational excellence.

Milan, 12 november 2024 – In the report published today on Il Sole 24 Ore, we are among the Italy’s Growth Champions 2025. The award is dedicated to the 500 Italian companies that have experienced the highest revenue growth in the three-year period from 2020 to 2023.

It is a significant public recognition that confirms the high potential of our company, capable of competing increasingly on the international stage.

With an average annual growth of 40% PHSE ranks 293.

Check out the complete list of 500 companies, compiled by il Sole 24 Ore and Statista.

The rankings are available online at the following link:

Ranking Leader della Crescita 2025

Here, the link to the online dossier:

Dossier Leader della Crescita 2025

We are delighted to share our participation at The ONE Forum, organized by the National Marrow Donor Program (NMDP) in Minneapolis. This unique and impactful event brought together over 2,000 professionals from the cell therapy ecosystem to collaborate and shape the future of this life-saving field.

Representing the PHSE Group, our teams from PHSE and Bio Transportes – a PHSE company proudly contributed to this visionary event. Together, we share NMDP’s mission to expand access to life-saving cell therapies for patients battling cancer and blood diseases.

At PHSE, we specialize in providing the highest standard of logistics for time-critical and temperature-sensitive shipments, ensuring patient safety and reliability. Our solutions include:

• Time-Critical and Temperature-Sensitive Logistics: From donor to patient, we handle every step, including temperature-controlled air freight, onboard couriers, last-mile distribution, and white-glove logistics services.
• Global Reliability and Security: We ensure shipments are 100% secure and reliable anywhere in the world.
• Route Risk Assessments: Our meticulous planning ensures zero-defect shipments every time.
• Transparency and Traceability: We provide global temperature and location monitoring for every shipment.
• Certified Packaging Solutions: Our certified thermal parcels and cryogenic dewars guarantee the integrity of cell therapy materials.
• 24/7 Support: Always available, always responsive.

We are honored to have been among the sponsors of this influential event, contributing to a shared vision of improving patient outcomes through innovative logistics solutions. By supporting initiatives like The ONE Forum, we reaffirm our commitment to advancing access to transformative therapies and improving lives worldwide.

Invited by the Fondazione Banca dei Tessuti del Veneto ETS, one of the most important tissue banks in Italy and Europe, we attended the first A.I.BA.T. National Congress (Italian Association of Tissue Banks).

During the event, Gianluca Meneguzzi shared PHSE’s expertise in transporting tissues such as bone, cardiac, vascular, and amniotic membrane, from donor to patient. For years, we have worked closely with ETS to ensure the daily temperature-controlled transport of tissues from the bank to operating theatres.

We are truly proud to be a partner of a center of excellence that in 2023 alone enabled over 6,000 surgeries, improving and saving countless lives.

A special thanks to Diletta Trojan and the A.I.BA.T. scientific committee for kindly inviting us to take part in this important event.

Ocotober 22, Milan – PHSE joins Nuclear Medicine Europe, the Industrial Association representing the leading pharmaceutical and imaging equipment companies in the field of nuclear medicine throughout Europe. Today’s handshake at EANM 2024 Congress between Martinus Blauwhoff, President of Nuclear Medicine Europe, and Paul Rice, Chief Development Officer of PHSE International, kicks off the valuable partnership.

“We have identified the Nuclear Medicine Europe Association as an opportunity to engage with industry experts, ranging from pharmaceutical companies to reactor operators worldwide, which we see as an essential part of our continuous improvement in offering highly specialised global transport services for the radiopharmaceutical market. Our first-hand involvement in working groups on topics of mutual interest, ranging from Security Of Supply, Therapy, Regulatory Affairs & Quality, and the Transport, will hopefully help bring real value to the complex radiopharmaceutical supply chain. While in the past drug distribution was considered the last chain in the manufacturing process, we strongly believe that logistics is increasingly a key asset and critical success factor in meeting the association’s challenges of Innovation, Healthcare For Everyone and Patient Safety within the sector. The three fundamental pillars that drive our daily actions as well”, said Paul Rice.

Milan, 2 October 2024 – PHSE, a leading group in temperature-controlled, and time critical pharmaceutical logistics, announces that it has completed the acquisition of 100% of Moving Forward International GmbH (MFI), a German freight forwarding company active in the international shipment (import and export from Germany) of pharmaceuticals, with a strong specialisation in the transport of radiopharmaceuticals, the new frontier in cancer therapies.

The transaction confirms the PHSE Group’s focus on the Radio Pharma market in order to meet the growing demand from large pharmaceutical companies for highly specialised global transport services capable of guaranteeing the delivery of products with a very short shelf-life (even within 24/48 hours) to the patient. The acquisition also provides the Group with entry into a new and strategic key market, Germany, Europe’s leading pharmaceutical market.

“We are excited to welcome Moving Forward International to our Group. MFI’s assets and expertise in radiopharmaceuticals further expand our GDP-compliant and IATA-certified European network for healthcare distribution by land and air worldwide. They will also accelerate our positive growth in Radio Pharma distribution, in which PHSE is one of the pioneers, having started operations in this specialist segment over a decade ago. Today, as well as our own increasing footprint and more than 70 specialist vehicles (15% of the PHSE fleet), we have an extensive global network of qualified agents which enables us to deliver both international and domestic solutions to our customers. We will further expand our own footprint in the coming years, to meet the growing needs of the market”, said Eddy De Vita, Executive Chairman of PHSE Group.

CEO Dario Guerrera and his expert team, will continue to lead the MFI business, which has its operational headquarters and warehousing at Frankfurt Airport, Europe’s first cargo hub, and will be supported by the broader PHSE Group capabilities.

“I am excited and proud to join the PHSE family, and to be able to bring even more capability and experience to support our customers”, commented Dario Guerra, CEO of MFI.

The PHSE Group expects to end 2024 with consolidated revenues of more than 100 million euros.

The transaction was concluded with the financial support of SIMEST, which positively assessed PHSE’s international development strategy and, in particular, the acquisition of MFI.

Fabio Mioli joins the PHSE Group today. As of 1 January 2025, he will assume the role of head of PHSE International, the Group’s sub-holding in which all foreign activities are concentrated, reporting directly to Eddy De Vita, Executive President of PHSE Group. Fabio Mioli assumes this responsibility from Graham Inglis, who has reorganised and developed the Group’s International business since 2020, and who will continue to lead this business until 31 December 2024, thus enabling an organized transition.

Fabio Mioli brings to the Group a wealth of experience in the Life Sciences Healthcare sector, having occupied senior roles in the commercial, strategic, purchasing, operations and supply chain areas for both pharmaceutical companies (Wyeth Pharmaceuticals, Schering-Plough and Procter Gamble) and service companies (such as Alliance Boots, DHL Supply Chain and UPS Healthcare, where he held the positions of Commercial Affairs Dir. GM, BU Director of Hospital, Specialty Pharma, Medical Devices and Country Manager Healthcare South Europe).

“Fabio’s appointment represents an exciting development for PHSE International. In this new position, he will be responsible for driving our growth in Europe, America and Asia, both organically and through strategic acquisitions. This is work already started by Graham Inglis, whom I would very much like to thank”, commented Eddy De Vita, Executive President of the company.

Since joining the business, Graham Inglis has contributed to the Group’s overall development, as well as growing the foreign business and delivering important results for PHSE International. Achievements include the rationalisation of the UK, US and Singapore branches, the opening of the Spanish hub, the three acquisitions in the UK, India and Brazil; and, further acquisitions, already at an advanced stage of development, are likely to follow in the coming months. Graham Inglis will remain as a member of the Board of Directors of PHSE, and will continue to support the strategic development of the Group.

The turnover of the Group, one of the world’s leading players in temperature-controlled Healthcare transport and last-mile distribution, has more than tripled in four years, rising from around € 27 million in 2019 to around € 86 million in 2023 (cagr +33%) also thanks to the completion of five acquisitions, three of which abroad (UK, India and Brazil) and two in Italy. These acquisitions have supported the development of new services for customers, including direct-to-patient, ground and air transport of radiopharmaceuticals and cell gene therapies, and strengthened the Group’s international capabilities.

Innovation and sustainability challenges are pushing us to find new solutions to be closer to our patients.

But how is it possible to bring the place of care closer and closer to people? How will the healthcare industry and supplychain have to organize themselves? What are the next challenges to overcome?

This event, organized by PHSE and PHD Life Science, in collaboration with Humanitas Research Hospital and with the media partnership of EDRA – FARMACISTA33, will be a common moment where we can explore the hospital of the future and recognize what will be these next challenges between innovation, research, sustainability and patientcenteredness, from a multidisciplinary perspective.

During the event, hosted by Sky Tg24 journalist Tonia Cartolano, important speakers will share their thoughts on current trends, projects and applications:

• Matteo Giovanni Della Porta, Head, Leukemia Unit – Cancer Center, Humanitas Research Hospital Full Professor of Hematology, Humanitas University
• Damiano Greco, Logistics Operations Country Lead, MSD
• Marcello Pani, Director UOC Hospital Pharmacy, Policlinico Universitario A. Gemelli IRCCS Roma
• Pierluigi Petrone, Presidentt Assoram e Vice President Farmindustria
• Beatrice Salvatori, Scientist Project Manager, Negedia
• Victor Savevski, Chief Innovation Officer e AI Center Director, Humanitas
• Marco Gorini, Project Head Digital Health Innovation, Astrazeneca
• Danilo De Spirito, Market Innovation Access Head, Bayer
• Annalisa Scopinaro, President UNIAMO, Federazione Italiana Malattie Rare
• Tiziana Mele, Managing Director, Lundbeck

  Register now now:
  https://lnkd.in/dZST6bCT

  For more information and to discover the program, visit:
  https://lnkd.in/dZST6bCT